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ABSTRACT
Studies using K14E6/K14E7 transgenic mice expressing E6 and E7 oncoprotein 
of human papillomavirus type 16 (HPV16) have demonstrated that estrogen (E2) is 
required for the genesis and growth of cervical cancer. Our prior study using the same 
mouse model has showed that progestin drug medroxyprogesterone acetate (MPA) 
promotes regression of primary cervical cancer. In the present study, we use the same 
transgenic mouse model to determine whether the cancer recurs after MPA therapy. 
Cervical cancer recurred even if MPA treatment was continued. Unlike primary cervical 
cancer, the cancer recurred even in the absence of exogenous E2 when MPA treatment 
was ceased. Furthermore, recurrent cervical cancer did not fully regress upon MPA 
treatment. Our results support that MPA fails to completely eliminate primary cervical 
cancer cells and that remaining cancer cells grow independent of exogenous E2 and 
are refractory to MPA.
INTRODUCTION
High−risk human papillomaviruses (HPVs) are 
causally associated with various human cancers, among 
which cervical cancer is most notable [1]. E6 and E7 viral 
oncoproteins are primarily responsible for the tumorigenic 
potential of these viruses. Among many cellular proteins 
interacting with these viral oncoproteins, p53 and pRb 
tumor suppressor are the most prominent target of E6 and 
E7, respectively [2]. Among more than a dozen high−
risk HPVs, HPV16 is most commonly found in cancer, 
followed by HPV18 [1]. Worldwide, cervical cancer is 
the fourth most common cancer and the fourth leading 
cause of death by cancer in women [3]. The Pap test and 
prophylactic HPV vaccines are effective in preventing 
cervical cancer [4]. However, they are not readily available 
to most women in developing countries and women of low 
socio−economic status in some developed countries [5]. 
Current therapies for advanced or recurrent cervical cancer 
are not effective [6]. The development of effective therapy 
for cervical cancer is urgently needed.   
While most women are infected with high−risk 
HPVs during their lifetime, only a small fraction of 
women succumb to cervical cancer, and precancerous 
lesion called cervical intraepithelial neoplasia (CIN) often 
regresses spontaneously [7]. These observations suggest 
that HPV is not sufficient and other cofactors are required 
for cervical carcinogenesis. In HPV−infected women who 
have used oral contraceptives compared to those who have 
not, the risk of developing cervical cancer is increased in 
proportion to the duration of use [8]. In HPV−infected 
women, the risk for cervical cancer in women with 
multiple full−term pregnancies is significantly higher 
compared to nulliparous women [9]. These observations 





) may play a role in HPV−induced 
cervical cancer. Epidemiological studies looking at 
individual roles of these hormones in cervical cancer, 
however, have been inconclusive mainly due to the lack 
of data stratification based on the status of high−risk HPV 
and low cervical cancer incidence in the study population 
(i.e., post−menopausal women). A few clinical trials have 
not been informative due to short follow−up period, poor 
drug choice, and/or underpowered multivariable analyses. 
These studies are discussed in other publications [10, 11].
Transgenic mouse models expressing HPV16 E6 
and/or E7 have been powerful tools to understand the 
molecular mechanism of cervical carcinogenesis. In these 
                  Research Paper
Oncotarget2373www.impactjournals.com/oncotarget
mice, expression of E6 and E7 is targeted to the squamous 
epithelium, which is the natural target for productive HPV 
infection [12–14]. Consistent with the notion that HPV is 
not sufficient, the development of cervical cancer in these 
mice requires both HPV oncogenes and chronic treatment 
with low levels of exogenous E
2
 [12, 15]. Cervical cancer 
arising in the HPV transgenic mouse model recapitulates 
key aspects of the human cancer including cofactor−
dependent progressive disease development, cancer 
development in the transformation zone, and expression 
of similar biomarkers [12, 15, 16]. Estrogen receptor α 
(ERα) is required for cervical carcinogenesis in the HPV 
transgenic mice [17, 18]. One of ERα target genes in the 
cervix is Pgr coding for progesterone receptor (PR) [19]. 
ERα and PR are ligand−dependent transcription factors 
belonging to the nuclear receptor superfamily [20]. PR−
positive cervical cancer patients have better prognosis after 
radiation therapy than PR−negative cancer patients [21]. 
Although it needs to be confirmed by independent studies, 
the use of progestin drug medroxyprogesterone acetate 
(MPA) is inversely associated with cervical neoplastic 





induced cell proliferation and promotes apoptosis in the 
murine cervical epithelium in the PR−dependent manner 
[19]. While PR is expressed in the HPV transgenic mouse 
model for cervical cancer, its activity is minimal because 
P
4
 levels are kept low [10, 23]. These observations suggest 
that PR may be a ligand−dependent tumor suppressor in 
cervical cancer. In agreement, MPA promotes regression of 
cervical cancer in the HPV transgenic mouse model [23]. 
In the present study, we demonstrate that cervical cancer 
recurs after MPA therapy. We also show that, although PR 
is expressed, the recurring cancer is refractory to MPA. 
RESULTS
Cervical cancer recurs after MPA treatment is 
ceased
We previously showed that MPA promoted 
regression of cervical cancer in K14E6/K14E7 double 
transgenic mice [23]. We sought to determine whether 
the cancer recurs after MPA therapy. K14E6/K14E7 mice 
were treated with E
2
 for 6 months, and one group of mice 
were sacrificed immediately (primary group; Figure 1A). 
All seven mice in this group had cervical cancer (Table 1), 
indicating that all identically treated mice in other groups 
illustrated in Figure 1A had the cancer before further 
treatments. Another group of mice were subsequently 
treated with MPA for 2 months (therapy group; Figure 1A), 
and none of six mice had cervical cancer and CIN lesions 
(Table 1). These results indicated that cervical cancer 
and CIN regressed upon MPA treatment as previously 
demonstrated [23]. The third group was initially treated 
identically to the therapy group, and then retreated with 
E
2
 for 2 months [recurrence (+E
2
) group; Figure 1A]. 
All six mice in this group had cervical cancer and CIN 
lesions (Table 1). As a control, a group of mice were left 
untreated for first 6 months and then treated with MPA for 
2 months followed by E
2
 treatment for 2 additional months 
(De Novo group; Figure 1A). Cervical cancer arising in 
this group was considered as new disease based on prior 
results that, in HPV transgenic mice expressing E6 and 
E7, cervical cancer did not develop without exogenous E
2
 
and was regressed by MPA [12, 23]. In this group, cervical 
cancer developed in four of sixteen mice (25%) (Table 1), 
which was significantly different from cancer incidence 
of the recurrence (+E
2
) group (P = 0.002). These results 
indicated that most of cervical cancers in the recurrence 
(+E
2
) group were recurring diseases rather than newly 
arising cancers. 
To determine whether exogenous E
2
 is required 
for recurrence of cervical cancer, the recurrence (−E
2
) 
group was treated identically to the therapy group for 
the first 8 months, and then left untreated for 2 months 
(Figure 1A). All six mice in the group had cervical cancer 
(Table 1), which was significantly different from the De 
Novo group (P = 0.002). Cervical cancer and epithelia in 
recurrence (−E
2
) and recurrence (+E
2
) group were similar 
(Figure 1B–1C). The results indicated that cervical cancer 
recurs independent of exogenous E
2
. Vaginal cancer 
develops in the same mouse model, and MPA promotes its 
regression [23]. Vaginal cancer incidence in the recurrence 
groups was significantly greater than the De Novo group 
(P = 0.05), indicating that vaginal cancer also recurred 
after MPA therapy independent of exogenous E
2
 (Table 1). 
MPA fails to prevent recurrence of cervical 
cancer
We next sought to determine whether cervical cancer 
recurs if MPA treatment is continued. After MPA therapy, 
K14E6/K14E7 double transgenic mice were co-treated 
with E
2
 and MPA as shown in Figure 1A (Prevention 
group). All seven mice in this group had cervical cancer 
(Table 1). Cancer incidence in this group was significantly 
different from the therapy group (P = 0.0006). More 
importantly, the cancer incidence (100%) was identical 
to the recurrence (+E
2
) group and significantly greater 
than De Novo group (Table 1). These results indicate that 
cervical cancer recurred even in the presence of MPA. 
While the entire cervical epithelium in the therapy group 
contained cells with clear cytoplasm, not all epithelia of 
the prevention group had such cells (Figure 1B). Similarly, 
in the prevention group, some cervical cancers had cells 
with clear cytoplasm, but most did not (Figure 1C; data 
not shown). The clear cytoplasm is indicative of cervical 
mucinification induced by MPA [19, 23].
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 did not affect the incidence 
of recurrent cervical cancer, we sought to further 
characterize potential role of exogenous E
2
 in recurrence 
of cervical cancer. Cancer multiplicity was increased in 
the recurrence groups compared to the primary group 
(Figure 2A and Table 1); however, it did not reach 
statistical significance (P = 0.07). Cancer multiplicity 
between recurrence (+E
2
) and recurrence (−E
2
) group 
was similar (Figure 2A and Table 1). Total invasion area 
and size of largest cancers in the recurrence (+E
2
) group 
were significantly larger than primary and recurrence 
(−E
2
) group (Figure 2B–2C). We next determined cell 
proliferation indices by analyzing BrdU incorporation. 
Percentages of BrdU−positive cells were similar among 
primary, recurrence (+E
2
), and recurrence (−E
2
) group 
(Figure 2D–2E), indicating that cancers proliferate at 
similar rates in all three groups. Ki67 staining showed 
similar results (Supplementary Figure S1A–S1B). 
Percentages of TUNEL−positive cervical cancer cells 
were similarly low in all three groups (Figure 2F–2G). 
We obtained similar results with cleaved caspase-3 
staining (Supplementary Figure S1C–S1D). These 
results indicate that proliferation and apoptosis do 




Cancer multiplicity in the prevention and 
recurrence (+E
2
) group was not significantly different 
(Figure 2A). Total invasion area and size of largest 
cancers in the prevention group were significantly smaller 
than the recurrence (+E
2
) group (P ≤ 0.05) (Figure 2B–
2C). Proliferation indices determined by BrdU IHC 
was not significantly different between the recurrence 
(+E
2
) and prevention group (Figure 2D and 2E). We 
obtained similar results with Ki67 IHC (Supplementary 
Figure S1A–S1B). Apoptosis indices determined by 








dysplasia Cancer incidence, %
Multiplicity  
(Mean ± S.E.M)CIN1 (VaIN1) CIN2 (VaIN2) CIN3 (VaIN3)
Primary 7 0 (0) 0 (1) 0 (4) 0 (1) 7 (1) 100 (14.3) 1.7 ± 0.2 (0.1 ± 0.1)
Therapy 6 6 (6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
De Novo 16 4 (6) 1 (2) 5 (4) 2 (1) 4 (3) 25 (18.8) 0.8 ± 0.4 (0.3 ± 0.1)
Recurrence (+E
2
) 6 0 (0) 0 (1) 0 (0) 0 (1) 6 (4) 100 (66.7)  3.0 ± 0.7 (2.0 ± 0.9)
Recurrence (−E
2
) 6 0 (1) 0 (1) 0 (0) 0 (0) 6 (4) 100 (66.7) 3.0 ± 0.4 (1.3 ± 0.5)
Prevention 7 0 (1) 0 (2) 0 (2) 0 (0) 7 (2) 100 (28.6) 2.1 ± 0.3 (0.3 ± 0.5)
Recurrence therapy 7# 0 (1) 0 (0) 0 (0) 0 (1) 7 (5) 100 (71.4) 3.1 ± 0.7 (0.9 ± 0.3)
Control 5 0 (1) 0 (0) 0 (1) 0 (0) 5 (3) 100 (60.0) 3.2 ± 0.5 (1.2 ± 0.6)
*Mice were scored histopathologically for the worst disease present in the cervix or, in parentheses, the vagina of each mouse. CIN, cervical intraepithelial neoplasia; VaIN, vaginal intraepithelial neoplasia. 
P < 0.01 compared to the other groups. #One mouse did not have mucinified cervical epithelium, suggesting that MPA treatment did not work in that mouse. This mouse was excluded from statistical analyses.
Figure 1: Cervical cancer recurs after MPA therapy. (A) Treatment regimens are depicted. K14E6/K14E7 mice were enrolled 
at 4−6 weeks of age. MPA, medroxyprogesterone acetate; E
2
, estrogen. (B) Shown are representative images of H&E−stained cervical 
epithelium from indicated groups. Scale bar, 50 μm. (C) Shown are representative images of H&E−stained cervical cancer from indicated 
groups. Scale bar, 50 μm.
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TUNEL assay were also similar between the two groups 
(Figure 2F–2G). Cleaved caspase-3 IHC results were 
consistent with TUNEL assay (Supplementary Figure 
S1C–S1D). These results suggest that MPA delays 
recurrence of cervical cancer but, once recurred, MPA 
does not inhibit cancer growth. 
Recurrent cervical cancers are refractory to 
MPA
We next sought to determine whether MPA 
promotes regression of recurrent cervical cancer. In order 
to induce recurrent cervical cancer, two additional groups 
of K14E6/K14E7 double transgenic mice were treated 
like the recurrence (+E
2
) group and then treated with MPA 
(recurrence therapy group) or vehicle (control group) 
for 2 additional months (Figure 3A). As expected, 5 of 
5 (100%) mice in the control group had cervical cancer 
(Table 1). In the recurrence therapy group, 7 of 7 (100%) 
mice had cervical cancer (Table 1). The cancer incidence 
in the therapy (0%) and recurrence therapy group (100%) 
was significantly different (P = 0.0006; Table 1). Mice in 
the recurrence therapy group had hypoplastic epithelia 
and epithelial cells with clear cytoplasm in the cervix 
(Figure 3B), indicating the functionality of MPA [23]. 
The cancers in the control group were well differentiated 
(Figure 3B). Consistently, they expressed cytokeratin 
10 (K10) (Figure 3C), marker for differentiated 
Figure 2: Exogenous E2 results in larger recurrent cervical cancer without affecting proliferation and apoptosis. 
(A) Exogenous E
2
 does not increase the number of recurrent cervical cancer. The number of cancer in each mouse is shown as box plot. 
Red lines show the medians and box limits indicate the 25th and 75th percentiles. Whiskers extend 1.5 times the interquartile range. 
A dot indicates outlier. Group sizes are indicated in Table 1. Rec., recurrence. (B) Exogenous E
2
 increases total invasion area. Total 
invasion area per mouse is shown as box plot as described in A. Group sizes are indicated in Table 1. *P = 0.01, **P = 0.05, ***P = 0.03. 
(C) Exogenous E
2
 induces larger recurrent cervical cancer. The size of largest cancer per mouse is shown as box plot as described in A. 
Group sizes are indicated in Table 1. *P = 0.02, **P = 0.05. (D) Exogenous E2 or MPA does not affect proliferation of recurring cervical 
cancer cells. Cervical cancer sections were stained for BrdU (green) to measure cell proliferation. Nuclei are shown in blue. Dotted lines 
separate cervical cancer (cc) from stroma (st). Scale bar, 50 μm. (E) Results shown in D. was quantified and shown as mean ± S.E.M. (n = 3). 
(F) Exogenous E
2
 or MPA does not influence apoptosis of recurrent cervical cancer. Cervical cancer sections were subjected to TUNEL 
assay. TUNEL+ cells are shown in green (see white arrows). Nuclei are shown in blue. Scale bar, 30 μm. (G) Results shown in F. was 
quantified and shown as mean ± S.E.M. (n = 3).
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squamous cells [24]. In the recurrence therapy 
group, the cancers were poorly differentiated and 
did not express K10 (Figure 3B–3C). Three mice 
had the cancer containing cells with clear cytoplasm 
(Figure 3B), indicative of mucinification [19]. These 
results indicate that MPA induces histological changes 
in recurrent cervical cancers, but does not eliminate 
them. Along with the observation that cervical 
cancer recurred even in the presence of MPA (see 
Figure 1A and Table 1), we conclude that recurrent 
cervical cancer is resistant to MPA. Recurrent vaginal 
cancer also did not regress after MPA treatment (Table 1).
MPA shrinks recurrent cervical cancer 
In agreement with the conclusion that recurrent 
cervical cancer is refractory to MPA, the cancer 
multiplicity was similar in the control and recurrence 
therapy group (Figure 4A and Table 1). However, total 
invasion area and largest cancer size were significantly 
smaller in the recurrence therapy group compared 
to the control group (Figure 4B–4C). Percentages of 
BrdU−positive cells were modestly, but significantly, 
decreased in the recurrence therapy group compared to 
the control group (Figure 4D–4E). Percentage of Ki67 
expressing cells was also significantly decreased in 
the recurrence therapy group compared to the control 
group (Supplementary Figure S2A–S2B). Percentages 
of TUNEL+ or cleaved caspase-3+ cells were not 
significantly different between the two groups (Figure 
4F–4G and Supplementary Figure S2C–S2D). These 
results suggest that MPA reduces the size of recurrent 
cervical cancer, at least in part, by inhibiting proliferation. 
They also indicate that recurrent cervical cancer is 
partially responsive to MPA. 
PR is expressed in recurrent cervical cancer 
The main target of MPA is PR [25]. As previously 
reported [23], cervical cancers in the primary group 
expressed PR (Figure 5A). PR expression was also 
evident in cervical cancers not only in the recurrence 
(+E
2
) and recurrence (−E
2
) but also in recurrence therapy 
and prevention group (Figure 5A). One of seven mice in 
the prevention group had cervical cancer that displayed 
reduced PR expression compared to the proximal 
epithelium and surrounding stroma as well as other 
cancers (Supplementary Figure S3). While the incidence 
of PR−positive cancer was not significantly different 
among all groups (P ≥ 0.5), it raised a possibility that PR 
loss may be responsible for a subset of recurring cervical 
cancers. Nonetheless, these results indicate that the loss of 
PR expression is not the major mechanism of recurrence 
and MPA resistance. ERα is required for cervical 
carcinogenesis in the HPV transgenic mouse model [18]. 
Cervical cancers in all groups expressed ERα (Figure 5B). 
Expression of MCM7, cervical cancer biomarker [16], was 
similar in all cancers (Figure 5C). 
DISCUSSION
MPA promotes regression of primary cervical cancer 
in the HPV transgenic mouse models [23]. Our results 
indicate that MPA fails to completely eliminate cancer 
cells because cervical cancer recurred at high frequency 
(100%) after MPA therapy (Table 1). Cervical cancer 
recurs after raloxifene therapy in the HPV transgenic 
mouse model; however, the incidence of cancer recurrence 
in the presence or absence of exogenous E
2
 is 72.8% 
(n = 11) and 40% (n = 10), respectively [26]. The lower 
rate of cancer recurrence suggests that inhibition of ERα 
Figure 3: MPA fails to regress recurrent cervical cancer. (A) Treatment regimens are shown. Mice were enrolled in the study 
at 4−6 weeks of age. (B) Recurrent cervical cancer remains after MPA therapy. Representative images of H&E−stained cervical tissue 
sections are shown. The number of mice with presented histology is indicated at the upper left corner. Black arrows point to cells with 
clear cytoplasm, indicative of mucinification. Scale bar, 50 μm. (C) K10 expression is decreased in recurrent cervical cancer treated with 
MPA. Cervical cancer sections were stained for K10 (green) and K14 (red). K14 stains cancer cells and K10 is a marker for differentiated 
squamous cells. Nuclei are shown in blue. Dotted lines separate cervical cancer (cc) from stroma (st). Scale bar, 50 μm. 
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by raloxifene may be more effective in treating primary 
cervical cancer than activating PR by MPA. It remains 
to be determined whether combination therapy with 
raloxifene and MPA results in no cancer recurrence.  
The development of primary cervical cancer in the 
HPV transgenic mice requires exogenous E
2
 [15, 27]. 
Cervical cancer recurred after MPA therapy even in the 
absence of exogenous E
2
 (Table 1). These observations 
highlight the difference between primary and recurrent 
cervical cancer. Although cervical cancer recurs in the 
absence of exogenous E
2
 after raloxifene therapy, the 
recurrence depends on endogenous E
2
 [26]. While primary 





 also contributes to the persistence of 
the primary cancer [28, 29]. These observations suggest 
that both exogenous and endogenous E
2
 contribute to 
development of primary and recurrent cervical cancer. 
Exogenous E
2
 did not increase incidence or multiplicity of 
recurrent cervical cancer, but resulted in larger recurrent 
cancer (Figure 2A–2C). However, proliferation and 
apoptosis indices of recurrent cancers were similar in the 
presence or absence of exogenous E
2
 (Figure 2D–2G). All 
mice were sacrificed 2 months after MPA therapy. Thus, we 
postulate that, in the presence of exogenous E
2
, the cancer 
recurred earlier and thus had grown for longer period of 
time compared to the cancer recurred without exogenous E
2
. 
It is notable that 4 of 16 mice in the De Novo group 
had cervical cancer (Table 1). These mice were treated 
with exogenous E
2
 only for 2 months starting at 9−9.5 
months of age (Figure 1A). Mice expressing E6 and E7 
do not succumb to cervical cancer when treated with 
exogenous E
2
 for 3 months starting at 1−1.5 month of age 
[27, 29]. Cervical cancer is also observed in K14E6/K14E7 
double transgenic mice treated with exogenous E
2
 for 
3 months starting at 8−8.5 months of age after raloxifene 
therapy [26]. These observations suggest that older mice 
are more susceptible to cervical carcinogenesis. Perhaps, 
cervical neoplastic disease develops spontaneously in 




Cancers in the recurrence therapy group were 
significantly smaller (> 2−fold) than the control group 
(Figure 4B–4C). The proliferation index of the recurrence 
therapy group was reduced only by 30% compared 
to the control group (Figure 4E). Thus, difference in 
proliferation does not fully account for the smaller cancer 
size in the recurrence therapy group. Differentiated 
epithelial cells are larger than undifferentiated cells 
[19]. Poorly differentiated cancers in the recurrence 
therapy group (Figure 3B–3C) may contribute to the 
difference in cancer size. Nonetheless, the fact that MPA 
decreased proliferation of recurrent cervical cancer raises 
a possibility that the recurrent cancer may fully regress 
if MPA treatment is prolonged. While we could not test 
possibility due to high morbidity of the mice older than 
the recurrence therapy group, cervical cancer recurred 
even in the presence of MPA (Table 1; prevention group). 
The morbidity was not related to cervical cancer [26, 30]. 
Figure 4: MPA decreases the size of recurrent cervical cancer by inhibiting proliferation. (A) MPA does not decrease 
multiplicity of recurrent cervical cancer. The number of recurrent cervical cancer per mouse is shown in box plot. Outliers are represented 
by dots. Control, n = 5; recurrence (rec.) therapy, n = 6. (B) MPA decreases total invasion area. Total invasion area per mouse is shown in 
box plot. *P = 0.04 (n = 5 for control; n = 6 for recurrence therapy). (C) MPA decreases the size of largest cancer. Largest cancer size per 
mouse is shown in box plot. *P = 0.03 (n = 5 for control; n = 6 for recurrence therapy). (D) MPA decreases cell proliferation in recurrent 
cervical cancer. Cervical cancer sections were stained for BrdU (green). Nuclei are shown in blue. Dotted lines separate cancer (cc) from 
stroma (st). Scale bar, 50 μm. (E) Quantification of results shown in D. is shown as mean ± S.E.M. (n = 3). *P = 0.05. (F) MPA does not 
influence apoptosis of cancer cells. Cervical cancer sections were subjected to TUNEL assay. TUNEL+ cells are shown in green (see white 
arrows). Nuclei are shown in blue. Scale bar, 50 μm. (G) Quantification of results shown in F. is shown as mean ± S.E.M. (n = 3).
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Therefore, we believe that the cancer would not disappear 
even if recurrent cervical cancer were treated with MPA 
for longer than 2 months. These results strongly support 
that recurrent cervical cancer is resistant to MPA. Perhaps, 
MPA–sensitive and –resistant cells are present in cervical 
cancer recurred in the absence of MPA. Our results 
indicated that PR was required for MPA’s therapeutic 
effect on cervical cancer (F.F. Mehta, S. Baik and S.H. 
Chung, unpublished data). The loss of PR expression 
is not the main mechanism of resistance to MPA 
(Figure 5A). It is possible that PR downstream signaling 
pathways responsible for anti−tumor activity are disrupted 
in the recurrent cervical cancer. MPA is used to treat early 
stage of endometrial cancer that expresses PR. However, 
most endometrial cancers eventually lose PR expression 
and stop responding to MPA [31, 32]. Interestingly, some 
PR−positive endometrial cancers do not respond to MPA 
therapy, and its mechanism remains to be determined [31]. 
PR is expressed in 20−40% of human cervical cancer [21, 
33–35]. If our results are translatable to women, some of 
patients with PR−positive cervical cancer may initially 
benefit from MPA therapy, but recurrence of MPA−
resistant cancer will be anticipated.
Our results demonstrated that cervical cancer recurred 
at high frequency after MPA therapy and the recurring 
disease was not so responsive to the same therapy as primary 
cancer. While the results are discouraging with regard to the 
translational value, they provide a model system to study 
mechanisms of recurrence and therapy resistance of cervical 
cancer. Such mechanisms may be relevant to resistance of 
endometrial cancer to MPA.  Further studies to identify PR 
target genes and pathways that mediate anti-cervical cancer 
activity of MPA are warranted.
MATERIALS AND METHODS
Transgenic mice and treatments
The K14E6 and K14E7 transgenic mice have been 
described previously [13, 14]. K14E6/K14E7 double 
transgenic mice were generated by mating K14E7 
hemizygote males with K14E6 homozygous females. Mice 
Figure 5: PR, ERα, and MCM7 are expressed in recurrent cervical cancer. (A) Cancer recurrence and MPA resistance are not 
due to loss of PR expression. Seven cervical cancers per group were stained for PR (red) and representative images are shown. Nuclei are 
shown in blue. A cervical cancer section from K14E7/Pgr−/− (PRKO) was used as negative control. Dotted lines separate cervical cancer 
(cc) from surrounding stroma (st). Note that PR is expressed in recurrence (rec.) therapy and prevention group. Scale bar, 50 μm. (B) ERα 
expression is similar in all cancers. Seven cervical cancers per group were stained for ERα (green) and representative images are shown. 
Nuclei are shown in blue. A cervical tissue section from Esr1−/− (ERαKO) was used as negative control. Dotted lines separate cervical cancer 
(cc) or epithelium (ep) from stroma (st). Scale bar, 50 μm. (C) MCM7 expression is similar in all cancers. Seven cervical cancers per group 
were stained for MCM7 (red), marker for E7 function and representative images are shown. Nuclei are shown in blue. Normal mouse IgG 
was used as negative control. Dotted lines separate cervical cancer (cc) from surrounding stroma (st). Scale bar, 30 μm.
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were genotyped by PCR. Four to six week old K14E6/
K14E7 virgin females were treated with slow−release 
17β−estradiol (E
2
) tablets (0.05 mg/60 days; Innovative 
Research of America, Sarasota, FL) as previously 
described [15]. Some mice were also subjected to monthly 
i.p. injection of MPA Injectable Suspension (SICOR 
Pharmaceuticals, Irvine, CA), which delivers 4.5 mg of 
MPA for a month [23]. All mice were i.p. injected with 
bromo−deoxyuridine (BrdU; 3.75 mg/mouse) 1 hour 
before collecting tissues. All procedures were approved 
by the University of Houston Institutional Animal Care 
and Use Committee. 
Tissue processing and histopathological analysis
 Reproductive tracts were fixed in 4% 
paraformaldehyde, embedded in paraffin, and serially 
sectioned at 5 μm thickness throughout the cervix. 
Hematoxylin and eosin (H&E) staining was carried out as 
previously described [23]. Every tenth slide was subjected 
to blinded histopathological analyses as previously 
described [15].
Immunohistochemistry and TUNEL assay
 For immunohistochemistry (IHC), sections 
were deparaffinized, rehydrated, and microwaved in 
10 mM sodium citrate buffer (pH 6.0) for 20 minutes. 
After incubation with blocking buffer (10% goat serum 
in PBS), the sections were incubated with primary 
antibodies as previously described [19, 36]. Anti−K14 
antibody (BioLegend, San Diego, CA) was diluted to 10% 
goat serum (1:1,000). The sections were subsequently 
incubated with secondary antibody conjugated with 
Alexa488 or 594 (Life Technologies). TUNEL assay was 
carried out using ApopTag Fluorescein in situ apoptosis 
detection kit according to the manufacturer’s instructions 
(Millipore). Nuclei were stained with Hoechst 33342.
Microscopy and digital image analyses
 Stained tissue sections were visualized by an 
Olympus BX51 microscope. Representative images were 
acquired with color (Olympus DP73) or cooled CCD 
monochrome cameras (Olympus XM10). Measurement 
of tumor size was carried out using the Olympus cellSens 
Dimension imaging software on images acquired with 
a 20X objective lens as previously described [28]. For 
quantification of BrdU− and TUNEL−positive cells, 
several random microscopic fields per cancer were 
analyzed. 
Statistical analyses
All statistical analyses were carried out using the 
MSTAT software (version 6.1.4), which is freely available 
at mcardle.wisc.edu/mstat. Cancer incidence was analyzed 
using one−sided Fisher’s exact test. One−sided Wilcoxon 
rank sum test was used for proliferative and apoptotic 
indices, multiplicity, and cancer size.  
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